Business · 31/05/2016
FDA Renews Psychopharmacologic Drugs Advisory Committee for 2 Years
The FDA is renewing the Psychopharmacologic Drugs Advisory Committee for an additional 2 years, with the new charter set to expire on June 4, 2018.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →